London, UK and Beijing, China, 21 November 2014: MRC Technology and Yabao Pharmaceutical Co, Inc., a leading pharmaceutical company in China, today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease. Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialise the therapeutics in China, Taiwan and Hong Kong whilst MRC Technology retains rights in all other markets. Financial terms have… Read More
21 November 2014
Catherine Kettleborough elected to SLAS Europe Council
Congratulations to Catherine Kettleborough, MRC Technology’s Associate Director of Drug Discovery Biology, who has been elected to the SLAS Europe Council for three years starting January 2015!
10 November 2014
Scientists have identified chemicals that could protect vital organs from long-term damage following a heart attack or stroke, according to new research in mice, part-funded by the British Heart Foundation (BHF) and Medical Research Council (MRC).
6 November 2014
Five recent publications from our labs
17 October 2014
Project will investigate a small molecule solution for Macrophage migration inhibitory factor
13 October 2014
London, UK, 29 September 2014: MRC Technology (MRCT), a UK medical research charity, today announced the appointment of Dr. John Stageman as Chair of its Board of Directors, and who takes over from John Jeans, the charity’s Chair for the last six years. Dr Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research. He has held a number of international R&D senior management roles at AstraZeneca, from drug discovery through to global clinical development. Latterly he led the team responsible for developing AstraZeneca’s competitive… Read More
29 September 2014
The 24 July issue of SciBX contains an article about the Dementia Consortium with a quote from our Director of Drug Discovery, Justin Bryans. The full article is available on the SciBX site.
24 July 2014
The inwardly rectifying K+ channel KIR7.1 controls uterine excitability throughout pregnancy McCloskey, C., Rada, C., Bailey, E., McCavera, S., van den Berg, H. A., Atia, J., Rand, D. A., Shmygol, A., Chan, Y.-W., Quenby, S., Brosens, J. J., Vatish, M., Zhang, J., Denton, J. S., Taggart, M. J., Kettleborough, C., Tickle, D., Jerman, J., Wright, P., Dale, T., Kanumilli, S., Trezise, D. J., Thornton, S., Brown, P., Catalano, R., Lin, N., England, S. K. and Blanks, A. M. (2014) EMBO Mol Med. doi: 10.15252/emmm.201403944
24 July 2014
Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases
22 July 2014
The collaboration focuses on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics for the treatment of serious disease in the areas of oncology, inflammation and diabetes.
3 July 2014